Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2014-11-14 Capital/Financing Update
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or updates that shareholders should know about. The content describes the completion of a public sale of common stock shares, including details about the offering, proceeds, and placement agent. This is an update on the company's financing activities, specifically a registered direct placement of shares and related capital raising. It is not a full financial report, earnings release, or management discussion, but rather a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2014-11-14 English
QUARTERLY REPORT
Interim / Quarterly Report 9M 2014
2014-11-13 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 27, 2014, reporting a recent financing event involving the sale of common stock shares. It references a Registration Statement on Form S-1 and a prospectus supplement related to a public offering. The content focuses on the completion of a registered direct placement of common stock and details about the placement agent and proceeds. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The primary purpose is to update on capital raising activities. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length (6654 characters) supports it being a substantive filing rather than a brief announcement or certification.
2014-10-27 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 27, 2014, reporting a recent event on October 23, 2014. The content describes the completion of a registered direct placement of common stock shares, including details about the offering, proceeds, and placement agent. This is an update on a capital raising event, not a full financial report or earnings release. The document is about financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4553 characters, which is consistent with a detailed announcement rather than a brief notice or a full annual/interim report.
2014-10-27 English
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which reports a recent event related to the company. It details a registered direct placement of common stock, including the number of shares sold, gross proceeds, and related agreements. The document is not a full financial report, earnings release, or annual/interim report, but rather a regulatory filing reporting a financing event. It includes references to the Registration Statement and Prospectus but does not itself contain comprehensive financial statements or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6734 characters) supports it being a substantive filing rather than a brief announcement. Hence, the classification is CAP with high confidence.
2014-10-15 English
DANDRIT BIOTECH USA, INC. FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a completed public sale of shares (a registered direct placement) and details about the placement agent and the offering. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is primarily an update on a capital raising event. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document length is 4638 characters, which is sufficient to contain substantive information about the financing event, not just a brief announcement or reference. Therefore, the correct classification is CAP with high confidence.
2014-10-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.